profitdaddy
2 years ago
NEWS OUT-
CB Scientific, Inc. (CBSC) and Shenzhen Pump Medical Co., Ltd. Announce Cooperative Manufacturing Agreement for Chinese Market
Press Release | 08/23/2022
Shenzhen Pump Medical Co. Ltd. to formally become the recognized manufacturer of record for CBSC's myCam device, cloud-based software, and smartphone app in China.
SHENZHEN, CHINA and ESCONDIDO, CA / ACCESSWIRE / August 23, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, is pleased to announce that it has entered into a cooperative manufacturing agreement (CMA) with Shenzhen Pump Medical Co., Ltd. (Shenzhen Pump), a privately held, well-established medical device manufacturer, developer and distributor of cardiovascular medical equipment and devices based in Shenzhen, Nanshan, China.
Under the terms of the CMA, Shenzhen Pump will formally be recognized as the qualified manufacturer of record in China for the Company's innovative myCam cardiac event monitor, interactive cloud-based acquisition software, and the associated We Chat smartphone app. As a certified ISO 13485, and Quality Systems Regulations compliant device manufacturer in that country, Shenzhen Pump fulfills the manufacturing regulatory requirements of the National Medical Products Administration (NMPA - formally China's FDA) medical device regulatory approval process for the Company's myCam device in China.
"I am extremely excited to welcome Shenzhen Pump as our manufacturing partner in China," said Charles Martin, Chief Executive Officer of CB Scientific, Inc. "They have a reputation of manufacturing excellence in that country which we believe will facilitate completion of the final regulatory approval process steps necessary to be awarded a clearance to market from the NMPA for the myCam device in the Chinese market."
While timing of the overall product approval process was temporarily hindered by the COVID-19 pandemic, CBSC was able to continue accruing significant market effectiveness data. Since 2019, the Company's successful onsite field evaluation trial for myCam includes over 2.1 million patient interactions, with a 99+% efficiency performance rating, located at 46 different hospitals in Ningbo, Shenzhen, Dongguan, and Guangzhou, China.
CBSC plans to immediately commence collaboration with Shenzhen Pump to prepare their facility for myCam device manufacturing, deployment of a new Chinese cloud-based software portal for validation, test and support purposes, as well as development of an enhanced WeChat smartphone app to seamlessly function with the newly manufactured devices. Subsequent to a successful NMPA audit confirming Shenzhen Pump meets requisite manufacturing standards, a limited number of pre-production myCam devices will be placed with existing hospital evaluation locations for final validation performance testing.
As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
AskMuncher
3 years ago
$CBSC CB Scientific, Inc. Enters Beta-testing Phase for Its Updated Proprietary My-Cam Cardiac Event Monitor
Press Release | 12/14/2021
Updates to provide device improvements while maintaining the innovative core-functionality of CBSC's state-of-the-art cardiac event monitor
ESCONDIDO, CA / ACCESSWIRE / December 14, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced today that the company has entered the Beta testing phase for its updated My-Cam cardiac event monitoring device. The updated design provides improved power consumption, enhanced lead wire shielding, improved signal quality, and a more cost-effective part sourcing while maintaining its core functionality of being a state-of-the-art auto-trigger device.
As demand for the My-Cam device continues to grow throughout CB Scientific's subsidiaries and partners, CBSC's commitment to the manufacturing process, both domestically and internationally, will ensure that the company will be able to meet customer demand throughout the current supply chain crisis and beyond. The company anticipates that upon the completion of successful Beta testing, it will move into Pre-production testing (also known as User Acceptance Testing) in the coming weeks.
As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About CB Scientific, Inc.
CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
View source version on accesswire.com:
https://www.accesswire.com/677488/CB-Scientific-IncEnters-Beta-testing-Phase-for-Its-Updated-Proprietary-My-Cam-Cardiac-Event-Monitor
AskMuncher
3 years ago
$CBSC CB Scientific, Inc. Executes Manufacturing Letter of Intent with Shenzhen Pump Medical System Co., Ltd.
Press Release | 12/07/2021
Partnership to provide high volume manufacturing capability and facilitate obtaining requisite government approvals
ESCONDIDO, CA / ACCESSWIRE / December 7, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced Shenzhen Pump Medical System Co., Ltd. (SPMS), a leading Chinese developer, manufacturer, and distributor of medical equipment and devices focusing on cardiovascular diagnostic systems, has issued a formal Letter of Intent to manufacture the Company's products targeting key Southeast Asia markets including China, Malaysia, Thailand, Indonesia, and Singapore.
"This critical collaboration is indispensable, not only by establishing a prominent local manufacturing relationship in the region, but also in terms of securing validation from the U.S. Food and Federal Drug Administration (FDA), and seeking approval by the National Medical Products Administration (NMPA), previously the China Food and Drug Administration (CFDA), which is the institution responsible for pharmaceuticals and medical device regulations in China," said Charles Martin, Chief Executive Officer of CBSC. "Beyond the obvious manufacturing and regulatory approval advantages gained through this valuable relationship, the cooperative alliance will also provide multiple gateways directly into existing distribution channels throughout the region once we commence full-rate production."
As additional new developments occur, CB Scientific, Inc. plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About CB Scientific, Inc.
CB Scientific, Inc., through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
View source version on accesswire.com:
https://www.accesswire.com/676305/CB-Scientific-Inc-Executes-Manufacturing-Letter-of-Intent-with-Shenzhen-Pump-Medical-System-Co-Ltd
AskMuncher
3 years ago
$CBSC CB Scientific Files Application to Uplist to the OTCQB Venture Market
Press Release | 11/16/2021
Upgraded listing would provide increased transparency and enhanced trading efficiency
ESCONDIDO, CA / ACCESSWIRE / November 16, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") is pleased to announce that it has submitted its application to uplist to the OTCQB® Venture Market.
The application itself is not a guarantee of acceptance by OTC MARKETS to go from the Company's current OTC PINK status to uplisting onto the OTCQB®. However, CB Scientific previously engaged MaloneBailey LLP to conduct a Public Company Accounting Oversight Board (PCAOB) audit and has appointed sufficient independent directors, both key requirements to be considered for uplisting.
"If accepted, uplisting to the OTCQB® would be a critically important step for the Company as we continue to execute our business plan," said Charles Martin, Chief Executive Officer of CB Scientific. "Additionally, achieving such an auspicious milestone will certainly better position us to meet required listing standards as we work towards achieving one of our longer-term objectives of becoming a Nasdaq Capital Markets-listed company," he added.
The Company believes that an uplist to the OTCQB® would provide enhanced investor benefits, including more comprehensive compliance requirements, higher reporting standards, and greater access to analyst coverage.
As additional new developments occur, CB Scientific plans to make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.
About CB Scientific, Inc.
CB Scientific (https://cbscientificinc.com/), through its domestic and international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.
Company Contact Information:
Telephone: (888) 225-0870
Email: General Inquiries: info@cbscientificinc.com
Investor Inquiries: Robert Hesse - dorchco.bh@gmail.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
AskMuncher
4 years ago
$CBSC CB Scientific, Inc. (CBSC) Distributor Mango Wellness Comes to an Agreement to Provide Services to Three Major Hospital Chains in Thailand
Press Release | 03/16/2021
Successful introductory product trials result in an agreement by three major hospital chains to use the my-Cam device
ESCONDIDO, CA / ACCESSWIRE / March 16, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, announces today the anticipated addition of three major hospital chains to use Remote Cardiac Monitoring Services in Thailand using the proprietary my-Cam device and associated cloud-based software portal through their exclusive authorized distributor Mango Wellness Co., Ltd. (MWC).
Mango Wellness Co., Ltd., due to the successful on-site trial evaluations of our innovative my- Cam monitor and my-Cardia software portal in two regions of Thailand, has come to a formal agreement to provide Remote Cardiac Monitoring Services to three major hospital chains. Ramkhamhaeng Hospital (one of the five largest private hospital groups in Thailand consisting of 40 hospitals), Bangkok Hospital Nakon Ratchasima (one of the largest hospitals in NE Thailand), and Bangpakok9 Hospital have all agreed to offer my-Cam services through MWC to their physicians and associated patients beginning in April 2021. Mango Wellness Co., Ltd. and its subsidiary My Cardia Thailand, in further efforts to expand its product offering, continue trials of the my-Cam device, which today consists of 102 cardiologists in 42 hospitals totaling more than 1700 ambulatory remote cardiac event monitoring tests to date since the beginning of the year. As apart of these trials, MWC is also in negotiations with N Health Services, a purchasing subsidiary of Bangkok Dusit Medical Services (BDMS - one of the most prestigious hospital networks in the Asia-Pacific region), to secure a joint marketing partnership to promote MWC's Remote Cardiac Monitoring Services to the 48 hospitals in the BDMS network in Thailand.
"Mango Wellness is very pleased with how well the my-Cam device has performed and has been received throughout this introductory trial period in our country. With a diagnostic success rate of 85%, including endorsements from several electrophysiologists and cardiologists as part of these successful trials, I remain extremely optimistic about the tremendous potential of the Remote Cardiac Monitoring market in Thailand. During this test period, we received a testimonial from one of our trial physicians, Dr. Sura Boonrat of the Central Chest Institute of Thailand. Using the my-Cam device, he was able to capture a cardiac event, which he called a ‘pause', that occurred three times in one of his patients, who was transported to the hospital where he passed out. The detection of the ‘pause' led to the doctor implanting a pacemaker that day. In the words of the physician, and the patient, using the my-Cam device saved his life. This just further proves that using this alternative approach in Thailand can only help to advance the earlier detection of problematic cardiac rhythms in Thailand resulting in improved quality of life for patients here with potential heart issues, just as it did for Dr. Boonrat's patient." said Joe Chan, managing director for Mango Wellness and My Cardia Thailand.
Further penetration of the remote cardiac monitoring market into government hospitals and medical universities in Thailand continues, including Chulalongkorn, Siriraj, Rajavithi, Police General, and Phramongkutklao, to name a few.
CB Scientific plans to make further announcements to keep its shareholders, industry participants, and the public markets informed through press releases and regulatory filings as new developments occur.
CONTACT:
CB Scientific, Inc. Company Contact Information:
340 State Place
Escondido, CA 92029
Telephone number:
(888) 225-0870
Emails:
General inquires: info@cbscientificinc.com
Investor Inquiries: investor@cbscientificinc.com
Company Website and Social Media Outlets:
CB Scientific, Inc - CBSC website, Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
Mango Wellness Co., Ltd./My Cardia Thailand Co., Ltd. Company Contact Information:
Mango Wellness Co., Ltd.
Glas Haus Building, Level P, Unit PO1
1 Sukhumvit 25, North Klongtoey
Wattana, Bangkok, Thailand 10110
My Cardia Thailand Co., Ltd.
190 Sutthisan Road, Intersection 1
Ratchadaphisek, Dindaeng
Bangkok, Thailand 10400
Telephone number:
+66 (0) 21015576 - Mango Wellness
+66 (0) 971566481 - My Cardia Thailand
Emails:
General inquires: info@mangowellnessthailand.com
General inquires: info@mycardiathailand.com
Company Website and Social Media Outlets:
Mango Wellness Co., Ltd. website, Twitter, Facebook, Instagram, and YouTube
My Cardia Thailand Co., Ltd. website, Facebook, and YouTube
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
View source version on accesswire.com:
https://www.accesswire.com/635686/CB-Scientific-Inc-CBSC-Distributor-Mango-Wellness-Comes-to-an-Agreement-to-Provide-Services-to-Three-Major-Hospital-Chains-in-Thailand
ProfitScout
4 years ago
Excellent to see the new agreement for CBSC to begin providing its life saving cardiac monitoring to multiple hospitals in Thailand. This can mean so much to a great many new patients and further validate the CBSC my-Cam technology package.
CB Scientific, Inc. (CBSC) Distributor Mango Wellness Comes to an Agreement to Provide Services to Three Major Hospital Chains in Thailand
Successful introductory product trials result in an agreement by three major hospital chains to use the my-Cam device
ESCONDIDO, CA / ACCESSWIRE / March 16, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, announces today the anticipated addition of three major hospital chains to use Remote Cardiac Monitoring Services in Thailand using the proprietary my-Cam device and associated cloud-based software portal through their exclusive authorized distributor Mango Wellness Co., Ltd. (MWC).
Mango Wellness Co., Ltd., due to the successful on-site trial evaluations of our innovative my- Cam monitor and my-Cardia software portal in two regions of Thailand, has come to a formal agreement to provide Remote Cardiac Monitoring Services to three major hospital chains. Ramkhamhaeng Hospital (one of the five largest private hospital groups in Thailand consisting of 40 hospitals), Bangkok Hospital Nakon Ratchasima (one of the largest hospitals in NE Thailand), and Bangpakok9 Hospital have all agreed to offer my-Cam services through MWC to their physicians and associated patients beginning in April 2021. Mango Wellness Co., Ltd. and its subsidiary My Cardia Thailand, in further efforts to expand its product offering, continue trials of the my-Cam device, which today consists of 102 cardiologists in 42 hospitals totaling more than 1700 ambulatory remote cardiac event monitoring tests to date since the beginning of the year. As apart of these trials, MWC is also in negotiations with N Health Services, a purchasing subsidiary of Bangkok Dusit Medical Services (BDMS - one of the most prestigious hospital networks in the Asia-Pacific region), to secure a joint marketing partnership to promote MWC's Remote Cardiac Monitoring Services to the 48 hospitals in the BDMS network in Thailand.
"Mango Wellness is very pleased with how well the my-Cam device has performed and has been received throughout this introductory trial period in our country. With a diagnostic success rate of 85%, including endorsements from several electrophysiologists and cardiologists as part of these successful trials, I remain extremely optimistic about the tremendous potential of the Remote Cardiac Monitoring market in Thailand. During this test period, we received a testimonial from one of our trial physicians, Dr. Sura Boonrat of the Central Chest Institute of Thailand. Using the my-Cam device, he was able to capture a cardiac event, which he called a ‘pause', that occurred three times in one of his patients, who was transported to the hospital where he passed out. The detection of the ‘pause' led to the doctor implanting a pacemaker that day. In the words of the physician, and the patient, using the my-Cam device saved his life. This just further proves that using this alternative approach in Thailand can only help to advance the earlier detection of problematic cardiac rhythms in Thailand resulting in improved quality of life for patients here with potential heart issues, just as it did for Dr. Boonrat's patient." said Joe Chan, managing director for Mango Wellness and My Cardia Thailand.
Further penetration of the remote cardiac monitoring market into government hospitals and medical universities in Thailand continues, including Chulalongkorn, Siriraj, Rajavithi, Police General, and Phramongkutklao, to name a few.
CB Scientific plans to make further announcements to keep its shareholders, industry participants, and the public markets informed through press releases and regulatory filings as new developments occur.
CONTACT:
CB Scientific, Inc. Company Contact Information:
340 State Place
Escondido, CA 92029
Telephone number:
(888) 225-0870
Emails:
General inquires: info@cbscientificinc.com
Investor Inquiries: investor@cbscientificinc.com
Company Website and Social Media Outlets:
CB Scientific, Inc - CBSC website, Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
Mango Wellness Co., Ltd./My Cardia Thailand Co., Ltd. Company Contact Information:
Mango Wellness Co., Ltd.
Glas Haus Building, Level P, Unit PO1
1 Sukhumvit 25, North Klongtoey
Wattana, Bangkok, Thailand 10110
My Cardia Thailand Co., Ltd.
190 Sutthisan Road, Intersection 1
Ratchadaphisek, Dindaeng
Bangkok, Thailand 10400
Telephone number:
+66 (0) 21015576 - Mango Wellness
+66 (0) 971566481 - My Cardia Thailand
Emails:
General inquires: info@mangowellnessthailand.com
General inquires: info@mycardiathailand.com
Company Website and Social Media Outlets:
Mango Wellness Co., Ltd. website, Twitter, Facebook, Instagram, and YouTube
My Cardia Thailand Co., Ltd. website, Facebook, and YouTube
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE: CB Scientific, Inc.
View source version on accesswire.com:
https://www.accesswire.com/635686/CB-Scientific-Inc-CBSC-Distributor-Mango-Wellness-Comes-to-an-Agreement-to-Provide-Services-to-Three-Major-Hospital-Chains-in-Thailand
ProfitScout
4 years ago
Nice feature profile on CBSC. Thanks for the link. I especially like the coverage of the CB Scientific leadership team and it's high qualifications.
From the story:
Interesting to note, CB’s President and CEO Charles ‘Chip’ Martin worked as the Senior Director of Global Sales for BioTelemetry (BEAT) from 2015 to 2018. He’s back!
The company has secured US FDA 510K Registration through My-Cardia (USA) Inc. with authorizations for Singapore, Malaysia and Thailand.
The killer management team, is not just scientists – but also businessmen with exceptional sales and marketing experience. “No sales, no marketing, no business!” And these folks know how to sell!
Charles “Chip” Martin CEO, President and Director
He has held positions in sales, marketing, and executive management in the non-invasive Ambulatory ECG marketplace for more than 35 years. His career in the cardiac medical market began with Oxford Medical in 1985 where he sold the first “real-time” Holter analysis software system and recording devices offered in the US in a four-state Midwest territory.
He was promoted to Eastern Regional Sales Manager for the company in 1987. Career highlights include Regional Sales Manager for Spacelabs (Holter, Ambulatory Blood Pressure), National Sales Manager and Director of Sales for Instromedix (Cardiac Event Monitoring – King of Hearts), VP Sales and Marketing for CardioComm Solutions (GEMS Acquisition ECG Software for Event & Pacer TTM follow-up), and VP of Business Development with Biomedical Systems (IDTF Services, Holter, AEM, MCT).
From 2014 to 2018, Chip worked as the Senior Director of Global Sales for BioTelemetry Inc. a widely recognized leading provider of remote cardiac monitoring diagnostic services in the US that is publicly traded on the NASDAQ exchange (BEAT). He held the position of SVP of Sales and Marketing for My-Cardia (USA) Inc. from 2018 to 2019 and was promoted to CEO and President of Prevent Health Care International Corporation in August 2019, assuming the same roles now at CB Scientific, Inc., as well as Director.
Robert Kelley CFO, Vice President and Director
He has extensive experience with high-growth companies from VC-backed high-technology startups to large public corporations in roles including founder, CTO/VP Engineering, EVP Strategic Marketing, Corporate Development. He has led multiple first-mover product teams developing novel enterprise technologies from high-performance computers, broadband networks, and storage, to enterprise software from manufacturing/ERP, financial/accounting, and data warehousing/BI.
His graduate studies and teaching includes Computer Science, Linguistics and Artificial Intelligence, Marketing, and Analytics. Rob is a Chartered Financial Analyst (CFA). Rob uses analytics and his technology experience to inform marketing strategy, evaluate emerging technologies, and understand the economic value for customers.
James E. Ott Director
He held several senior leadership positions in his twenty-eight-year career in the Ambulatory ECG and Clinical Research Trials arena. Upon earning his Master of Science in Biomedical Engineering at Marquette University in 1991, Jim joined Biomedical System in St. Louis, MO in 1992 as a Product Manager where he coordinated the design, development and marketing efforts of their cardiac diagnostic software platform lines.
He was promoted in 2000 to President of Biomedical Systems Cardiology Division where he managed all aspects of their Independent Diagnostic Testing Facility (IDTF) to include international direct and distributor capital equipment sales, IDTF cardiology lab staffing, technology, sales and marketing, customer service, and reimbursement and regulatory activities.
During this time he managed the design, development, and implementation of the company’s internet-based Holter data and report transfer platform (Data Exchange), their internet-based Holter analysis platform (MyHolter.com), and their Mobile Cardiac Telemetry (MCT) platform – the TruVue® Wireless ECG Monitoring System. Jim was an integral part of successful US patent submissions and granted approvals for all three of these applications in 2004, 2005, and 2013 where he is listed as one of the inventors.
ProfitScout
4 years ago
Good news from CBSC today on the expansion of the company's management team with a very qualified leader for the high growth Asia Pacific healthcare sector. Excellent to see that he is experienced in fund raising which should be very helpful to CBSC expansion plans going forward.
CB Scientific, Inc. Announces Appointment of New Director for Asia Pacific
CBSC has appointed Jeslie Chui as Director of Business Development Asia Pacific
Escondido, California--(Newsfile Corp. - March 2, 2021) - CB Scientific. Inc. (OTC Pink: CBSC) ("CBSC" or the "Company"), in an ongoing effort to expand its outreach in the Ambulatory Remote Cardiac Diagnostic Monitoring products and services market globally, is pleased to announce the appointment of Jeslie Chui as Director of Business Development Asia Pacific for CB Scientific Inc. effective March 1, 2021. In this position Mr. Chui will work to increase company recognition and awareness of CBSC and its subsidiary My-Cardia, identify and develop corporate strategies for expansion and the associated marketing platforms to support these strategies, and assist in corporate fundraising in the region. Through his various entrepreneurial roles in Hong Kong and China, Jeslie Chui has been instrumental in raising venture capital including financial advisory and business development for companies from a wide variety of industries throughout his career.
<embed src="https://www.youtube.com/v/rMUMauiRcVo" type="application/x-shockwave-flash" width="560" height="315" allowscriptaccess="always" allowfullscreen="true"></embed>
Cannot view this video? Visit:
For more than twenty years, Mr. Chui has been a renowned veteran financial market professional in the Asia Pacific region. His considerable knowledge and extensive work experience include new business development, IPO advisory, Deal structuring, private equity funding, and merger and acquisitions. Strategic management planning, product development, information system implementation and management, and legal compliance are other areas of his expertise. Throughout his career Jeslie has held positions with Mithera Capital, a US based Private Equity, as their Chief Marketing Officer and Head of Asia Pacific market; Chief Strategic Officer for Zhong Tai International Financial Holdings Ltd.; and Head of Wealth Management for China Galaxy International (a subsidiary of China Galaxy Securities) to name a few.
In addition to his new role with CBSC, Mr. Chui also serves as the Head of Corporate Advisory Services for CCTH, a founding member of AG China. He has earned several academic degrees including a Master of Engineering in Electronic Commerce from The University of Hong Kong; Executive Master of Business Administration from The Chinese University of Hong Kong; Master of Science in Investment Management from The Hong Kong University of Science and Technology; Master of Law (LLM) in Chinese Business Law from The Chinese University of Hong Kong; and Master of Corporate Governance with Distinction from the Hong Kong Polytechnic University. Jeslie Chui is also an Adjunct Professor for the College of Business at the City University of Hong Kong and an Honorary Professor at Huashang College for the Guangdong University of Finance and Economics and has authored 24 books on investment products and corporate finance.
Mr. Chui will work closely with our recently launched distributor Mango Wellness, in Thailand, and two distributors scheduled to be operational in the next few months in Malaysia and Singapore. He will help expedite the start-up process there, and working along with these distributors, identify other areas of expansion in the region for growth. In this new role he will also be a corporate liaison as part of our new Collaborative Partnership with Semacare and assist, as needed, in our ongoing efforts to complete the regulatory certification of our my-Cam device with the National Medical Products Administration (NMPA) in China.
"We welcome Jeslie Chui to our company. As Director of Business Development, Jeslie will be instrumental in helping to promote awareness and increase corporate recognition of CB Scientific Inc. in the Asia Pacific region. Through his efforts there, we look forward to expanding our outreach by providing state-of-the-art Remote Cardiac Monitoring through our My-Cardia products and services to help reduce the impact of heart disease in this area of the world through early detection improving the quality of life for patients," said Charles Martin, President and CEO of CB Scientific, Inc. in a statement.
CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.
CB Scientific Inc. Company Contact Information:340 State Place
Escondido, CA 92029
Telephone number:
(888) 225-0870
Emails:
General inquires: info@cbscientificinc.com
Investor Inquiries: investor@cbscientificinc.com
Company Website and Social Media Outlets:
CB Scientific, Inc. website, Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter
This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
https://orders.newsfilecorp.com/files/7804/75775_0c3d98b794838a08_logo.jpg
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/75775
https://www.newsfilecorp.com/newsinfo/75775/130
budfoxfun
4 years ago
February 23, 2021 / CB Scientific, Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), in an ongoing effort to expand its outreach in the Ambulatory Remote Cardiac Diagnostic Monitoring Services market in the United States, is pleased to announce a definitive purchase agreement to acquire Cardiolink Corporation, a Medicare-certified Independent Diagnostic Testing Facility (IDTF) based in Levittown, New York. Cardiolink was founded in 1979 and has been providing remote heart arrhythmia monitoring and cardiac support services to the medical community regionally for forty-two years.
This acquisition will provide CBSC with the ability to formally enter the rapidly growing Remote Patient Monitoring (RPM) arena in the US, on a national basis. RPM has become a dominate growth market in the medical field since 2017, primarily due to the increasing occurrence of cardiovascular (heart) disease. Cardiolink, through their 24/7/365 operation, uses state-of-the-art cardiac equipment and software to deliver a wide variety of remote ambulatory cardiac testing services to patients. These wearable devices include Mobile Cardiac Telemetry, Cardiac Event, Extended Holter, Standard Holter and Ambulatory Blood Pressure, all monitored by an experienced staff of well-trained, expert cardiac technicians. Cardiolink also provides remote Pacemaker TTM monitoring and INR heart testing. This acquisition will make CBSC an active player in the domestic Ambulatory Remote Cardiac Diagnostic Monitoring Services market, which generated revenues of approximately US $778M in 2019, with projected future growth of 18% per year.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
IPO$
2 years ago
Natural Trader
3 years ago
WallStreetSurvivor
4 years ago
lucky__stock
4 years ago
Trooperstocks
4 years ago
StockHighAlert-
4 years ago
ED25
4 years ago
BlazingStocks
4 years ago
Hot Features
Premium
